Doc code :IDS
Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/08a (08-08)
Approved for use through 09/30/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	09718725
	Filing Date	2000-11-22
	First Named Inventor	Boyle, William J.
	Art Unit	1647
	Examiner Name	DeBerry, Regina M.
	Attorney Docket Number	A-378CIP2C3 Supp050609

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1	0816380	EP	A1	1998-07-01	Goto, M. et al.		☐
	2	9605309	WO	A2	1996-02-22	Friedman, Jeffrey M. et al.		☐

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]
	1	Adams et al., "Complementary DNA sequencing: expressed sequence tags and human genome project", Science, 252: 1651-1656 (1991)	☐
	2	Anderson W. F., "Prospects for Human Gene Therapy", Science, 226: 401-409 (1984)	☐
	3	Baylink et al., "The diagnosis and treatment of osteoporosis: future prospects", Mol. Med. Today, pgs 133-140 (1999)	☐
	4	Bork et al., "Go hunting in sequence databases but watch out for the traps", Trends in Genetics, 12: 425-427 (1996)	☐
	5	Bork, P., "Powers and pitfalls in sequence analysis: The 70% hurdle", Genome Research, 10: 398-400 (2000)	☐
	6	Brenner, S., "Errors in genome annotation", Trends in Genetics, 15: 132-133 (1999)	☐
	7	Buckel, "Recombinant proteins for therapy", Trends in Pharmacol. Sciences, 17(12): 450-456 (1996)	☐
	8	Crystal, R. G., "Transfer of Genes to Humans: Early Lessons and Obstacles to Success", Science, 270: 404-410 (1995)	☐
	9	Doerks et al., "Protein annotation: detective work for function prediction", Trends in Genetics, 14: 248-250 (1998)	☐
	10	Deonarain, M. P., "Ligand-targeted receptor-mediated vectors for gene delivery", Expert Opin. Ther. Patemts, 8(1): 53-69 (1998)	☐

		Application Number	09718725
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (**Not for submission under 37 CFR 1.99)**		Filing Date	2000-11-22
		First Named Inventor	Boyle, William J.
		Art Unit	1647
		Examiner Name	DeBerry, Regina M.
		Attorney Docket Number	A-378CIP2C3 Supp050609

	11	Eck et al., Gene-based therapy, Chapter 5, pgs 77-101, Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Ed., McGraw-Hill (1996)	☐
	12	Anderson, W. French,"The current status of clinical gene therapy", Human Gene Therapy, 13: 1261-1262 (2002)	☐
	13	Miller, N. et al., "Targeted vectors for gene therapy", FASEB J., 9: 190-199 (1995)	☐
	14	Orkin et al., www.nih.gov/news/panelrep.html, pgs 1-36 (Dec. 1995)	☐
	15	Rodan et al., "Therapeutic approaches to bone disease", Science, 289: 1508-1514 (2000)	☐
	16	Robbins et al., "Viral vectors for gene therapy", Pharmacol Ther, 80(1): 35-47 (1998)	☐
	17	Simonet et al., "Osteoprotegrin: A Novel Secreted Protein Involved in the Regulation of Bone Density", Cell, 89:309-319 (1997)	☐
	18	Skolnick et al., "From genes to protein structure and function: novel applications of computational approaches in the genomic era", Trends in Biotech, 18(1): 34-39 (2000)	☐
	19	Smith et al., "The challenges of genome sequence annotation or "The devil is in the details", Nature Biotechnology, 15: 1222-1223 (1997)	☐

If you wish to add additional non-patent literature document citation information please click the Add button | Add |

EXAMINER SIGNATURE

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (**Not for submission under 37 CFR 1.99)**	Application Number	09718725
	Filing Date	2000-11-22
	First Named Inventor	Boyle, William J.
	Art Unit	1647
	Examiner Name	DeBerry, Regina M.
	Attorney Docket Number	A-378CIP2C3 Supp050609

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.